Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

MNOV Insider Trading

MEDICINOVA INC | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at MEDICINOVA INC provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$0
Buys
$0
Sells

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2022-12-01 01:23 2022-11-28 Nagao Hideki Director SELL $2.25 6,754 $15,197 0 -100.0%
2022-11-24 00:01 2022-11-21 Nagao Hideki Director SELL $2.18 5,583 $12,160 6,754 -45.3%
2022-11-22 00:35 2022-11-17 Nagao Hideki Director SELL $2.18 309 $674 12,337 -2.4%
2021-03-16 04:30 2021-03-11 Nagao Hideki Director SELL $7.40 2,354 $17,420 12,646 -15.7%
2020-09-16 23:32 2020-09-15 Nagao Hideki Director SELL $5.78 1,000 $5,780 15,000 -6.3%
2020-03-17 02:17 2020-03-13 Matsuda Kazuko Director, Officer - Chief Medical Officer BUY $3.62 2,000 $7,240 111,746 +1.8%
2020-03-14 00:53 2020-03-13 Matsuda Kazuko Director, Officer - Chief Medical Officer BUY $3.62 2,000 $7,240 111,476 +1.8%
2020-03-13 01:39 2020-03-12 IWAKI YUICHI Director, Officer - President and CEO BUY $3.10 20,000 $62,000 780,683 +2.6%
2017-08-23 20:50 2017-08-21 Ishizaka Yoshio Director BUY $5.17 5,000 $25,850 10,000 +100.0%
2017-05-16 21:52 2017-05-15 Kobayashi Yutaka Director BUY $5.60 1,000 $5,600 25,000 +4.2%
2017-05-16 01:27 2017-05-12 Kobayashi Yutaka Director BUY $5.62 24,000 $134,880 24,000 +100.0%
2016-09-15 21:10 2016-09-15 Kobayashi Yutaka Director BUY $6.44 11,800 $75,992 81,800 +16.9%
2016-09-10 01:29 2016-09-09 Kobayashi Yutaka Director BUY $6.67 10,000 $66,700 70,000 +16.7%
2016-07-08 01:30 2016-07-05 OBrien Geoffrey Officer - Vice President OPT+S $8.00 3,300 $26,400 5,000 0.0%
2014-12-11 00:57 2014-12-10 Kobayashi Yutaka Director BUY $3.54 12,000 $42,480 60,000 +25.0%
2014-11-29 01:00 2014-11-26 Kobayashi Yutaka Director BUY $3.07 10,000 $30,700 48,000 +26.3%
2014-11-22 01:34 2014-11-20 Kobayashi Yutaka Director BUY $3.19 13,000 $41,470 38,000 +52.0%
2014-11-21 04:45 2014-11-19 Ishizaka Yoshio Director BUY $2.86 5,000 $14,300 5,000 +100.0%
2014-09-12 00:44 2014-09-11 Kobayashi Yutaka Director BUY $2.95 10,000 $29,500 25,000 +66.7%
2014-09-05 01:50 2014-09-03 Kobayashi Yutaka Director BUY $2.66 15,000 $39,849 15,000 +100.0%
2013-12-14 00:06 2013-12-12 Izumi Tatsuo Director SELL $2.10 71,270 $149,945 600,000 -10.6%
2013-11-20 01:40 2013-11-18 Izumi Tatsuo Director BUY $2.21 1,270 $2,812 671,270 +0.2%
2013-05-23 19:13 2013-05-21 Morris Arlene Director OPT+S $3.28 8,800 $28,877 0 0.0%
2013-05-16 01:02 2013-05-13 Izumi Tatsuo Director BUY $3.15 158,730 $500,000 158,730 +100.0%
2012-06-05 00:27 2012-05-31 Izumi Tatsuo Director BUY $1.81 5,200 $9,412 56,800 +10.1%
2012-05-31 01:10 2012-05-28 Izumi Tatsuo Director BUY $1.95 36,600 $71,268 51,600 +244.0%
2012-05-31 00:09 2012-05-29 O'Toole David D Director BUY $1.78 5,000 $8,900 5,000 +100.0%
2011-04-07 01:00 2011-03-29 Johnson Kirk William Officer - Chief Scientific Officer BUY $0.00 1,700 $0 1,700 +100.0%
2011-04-01 02:40 2011-03-29 Johnson Kirk William Officer - Chief Scientific Officer BUY $0.00 2,200 $0 2,200 +100.0%
2011-04-01 02:39 2011-03-29 COFFEE MICHAEL DENIS Officer - CBO & Interim CFO BUY $0.00 4,000 $0 4,000 +100.0%
2011-04-01 02:38 2011-03-29 IWAKI YUICHI Director, Officer - President and CEO BUY $0.00 50,000 $0 568,972 +9.6%
2009-07-31 00:26 2009-07-28 Kalafer Michael E Officer - Chief Medical Officer BUY $4.44 23,023 $102,139 31,744 +264.0%
2009-02-05 01:15 2009-02-02 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $2.25 1,800 $4,050 643,972 +0.3%
2009-01-28 00:55 2009-01-23 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $2.16 5,050 $10,909 642,172 +0.8%
2009-01-22 02:43 2009-01-16 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $2.03 3,271 $6,625 637,122 +0.5%
2009-01-16 03:10 2009-01-13 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $1.59 6,000 $9,548 633,851 +1.0%
2007-10-05 02:02 2007-10-04 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $8.21 1,300 $10,673 627,851 +0.2%
2007-10-03 23:11 2007-10-01 IWAKI YUICHI Director, Officer - Chief Executive Officer BUY $8.08 8,700 $70,332 626,551 +1.4%
SHOW ENTRIES
1-38 OF 38

How to Interpret $MNOV Trades

Not every insider transaction in MEDICINOVA INC is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $MNOV shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for MNOV

Insider activity data for MEDICINOVA INC is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $MNOV, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.